Among the various prenatal screenings offered during pregnancy, nuchal translucency (NT) testing is one that often comes up early in the first trimester. For women over 35, understanding what this test involves, what it measures, and how to interpret results can help reduce anxiety and support informed conversations with an obstetric provider.
It’s worth noting from the outset that a screening test is not a diagnostic test. Nuchal translucency screening provides a probability estimate, not a definitive answer. This distinction matters enormously when understanding your results, and a trained healthcare provider is the best resource for interpreting what any screening result means for your specific situation.
What Nuchal Translucency Screening Measures
Nuchal translucency refers to the fluid-filled space at the back of a developing fetus’s neck, visible on ultrasound typically between 11 and 13 weeks and 6 days of pregnancy. Research has shown that a larger-than-average NT measurement is associated with an increased probability of certain chromosomal conditions, including Down syndrome (trisomy 21), as well as some cardiac abnormalities.
According to the American College of Obstetricians and Gynecologists (ACOG), NT screening is most informative when combined with first-trimester blood tests (measuring PAPP-A and hCG levels), a combination often called first-trimester combined screening. This combined approach improves detection rates compared to NT measurement alone.
Why NT Testing Is Often Discussed After 35
The probability of certain chromosomal variations—including trisomy 21—increases with maternal age. This is well-documented in reproductive medicine and is one reason why prenatal screening conversations often take on added significance for women who become pregnant after 35.
However, it’s important to keep context in mind: most pregnancies after 35 result in chromosomally typical babies, and a “normal” NT measurement alongside reassuring blood markers provides meaningful reassurance. For women navigating pregnancy after 35, understanding the spectrum of screening options helps ensure you’re making decisions that align with your values and circumstances.
Screening vs. Diagnostic Testing
NT screening tells you about probability, not certainty. A “high-risk” result does not mean a diagnosis—it means further evaluation may be warranted. Diagnostic options, such as chorionic villus sampling (CVS) or amniocentesis, can provide definitive chromosomal information but carry a small procedural risk. Discussing the differences between screening and diagnostic testing with your OB/GYN or maternal-fetal medicine specialist is an important part of first-trimester care.
Understanding Your NT Measurement Results
NT measurements are typically reported in millimeters and compared against reference ranges based on gestational age and crown-rump length. A result is generally considered within the expected range when the NT measurement is below 3.0 mm, though laboratories and specialists may use slightly different thresholds.
When NT is combined with blood marker results and adjusted for maternal age, a risk ratio is calculated. For example, a result might be expressed as a 1-in-500 or 1-in-50 chance of a specific chromosomal condition. It is important to discuss what these ratios mean practically with your healthcare provider rather than interpreting a number in isolation.
Cell-Free DNA Screening as an Alternative or Addition
Cell-free DNA (cfDNA) screening—sometimes called NIPT or non-invasive prenatal testing—has become increasingly common and is now widely offered to pregnant women of all ages, not just those over 35. This blood test analyzes fetal DNA fragments in maternal blood and has higher sensitivity for certain chromosomal conditions than traditional first-trimester screening. However, it is still a screening test, not a diagnostic one. Some providers offer cfDNA as an option instead of or in addition to NT-based screening. Discussing which approach is most appropriate for your situation with your provider will help you make an informed choice.
What Happens After an NT Screening
If your NT measurement and blood markers are within the expected range and your combined risk ratio is reassuring, your provider will typically continue with routine prenatal care and may offer additional second-trimester screening options.
If results suggest increased probability for a chromosomal condition, your provider will likely offer a referral to a maternal-fetal medicine specialist and discuss options for diagnostic testing. Receiving a high-risk result can be stressful, and having support in place—whether through your provider, a genetic counselor, or trusted people in your life—can be valuable during this time.
The emotional aspects of navigating prenatal screening results are real and worth acknowledging. Many women find genetic counseling helpful not only for the informational component but also for the emotional support it provides during what can be an anxious period.
Genetic Counseling as a Resource
If you have questions about any aspect of prenatal screening—whether before, during, or after testing—a certified genetic counselor can be an invaluable resource. Genetic counselors are trained to explain risk information clearly, help you understand your options, and support you in making decisions that reflect your values. Your OB/GYN or midwife can provide a referral.
Frequently Asked Questions
Is nuchal translucency testing required?
NT testing is not mandatory. It is one of several prenatal screening options that expectant parents can choose to accept, decline, or modify based on their circumstances, values, and healthcare discussions. Your provider can help you understand what is recommended and what you might consider given your individual situation.
Does a high NT measurement mean my baby has Down syndrome?
No. An elevated NT measurement increases the probability of certain chromosomal conditions but does not confirm a diagnosis. Many pregnancies with higher NT measurements result in chromosomally typical babies, while some have other explanations such as cardiac variations. Diagnostic testing is needed to confirm any chromosomal finding.
When exactly is the NT scan performed?
The NT ultrasound is typically performed between 11 weeks and 13 weeks 6 days of pregnancy, when the fetal size allows for accurate measurement. Timing matters for the accuracy of the measurement, so it is generally scheduled deliberately within this window.
Is NT screening covered by insurance in the US?
Coverage varies by insurance plan. Many plans cover first-trimester prenatal screening, but it is worth confirming with your insurer before your appointment. Your OB’s billing office can also help clarify what is covered under your specific plan.
Key Takeaways
- Nuchal translucency screening measures fluid at the back of the fetal neck and, when combined with blood markers, provides a probability estimate for certain chromosomal conditions—not a diagnosis.
- After age 35, the probability of certain chromosomal variations increases, making prenatal screening conversations especially relevant—though most pregnancies after 35 result in chromosomally typical outcomes.
- A high-risk screening result is not a diagnosis; diagnostic testing options (CVS, amniocentesis, or further evaluation) can provide definitive information.
- Genetic counseling is available as a resource both for interpreting results and for emotional support during the decision-making process.
- Work with your OB/GYN or midwife to determine which combination of screening options aligns with your preferences and medical situation.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.